Payment overview · 2025
General Payments
$88.68
4 reported records · 3 companies
Healthcare provider profile · identity verified
Lori Ann Peters, DO
Allopathic & Osteopathic Physicians|Family Medicine · MCALESTER, OK · NPI 1861735482
Verified facts
What the public records show
CMS Open Payments records show Lori Ann Peters, DO received $88.68 in general payments during 2025 across 4 reported records.
Amgen Inc. accounted for 54.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $47.98 | 54.1% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $22.70 | 25.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.00 | 20.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $88.68 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $47.98 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $22.70 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 315 | 103 |
| Levothyroxine Sodium | Levothyroxine Sodium | 239 | 86 |
| Gabapentin | Gabapentin | 223 | 69 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 210 | 59 |
| Lisinopril | Lisinopril | 206 | 85 |
| Amlodipine Besylate | Amlodipine Besylate | 180 | 73 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 175 | 75 |
| Losartan Potassium | Losartan Potassium | 168 | 69 |
| Carvedilol | Carvedilol | 167 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 156 | 59 |
| Omeprazole | Omeprazole | 129 | 59 |
| Metformin Hcl | Metformin Hcl | 127 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 123 | 43 |
| Ozempic | Semaglutide | 109 | 35 |
| Montelukast Sodium | Montelukast Sodium | 108 | 34 |
| Furosemide | Furosemide | 105 | 42 |
| Potassium Chloride | Potassium Chloride | 102 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 99 | 36 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 95 | 23 |
| Buspirone Hcl | Buspirone Hcl | 88 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 85 | 27 |
| Trazodone Hcl | Trazodone Hcl | 82 | 35 |
| Famotidine | Famotidine | 81 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 74 | 29 |
| Eliquis | Apixaban | 71 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 69 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 67 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 67 | 22 |
| Ezetimibe | Ezetimibe | 64 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 59 | 19 |
| Sertraline Hcl | Sertraline Hcl | 58 | 25 |
| Celecoxib | Celecoxib | 56 | 15 |
| Donepezil Hcl | Donepezil Hcl | 56 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 21 |
| Meloxicam | Meloxicam | 53 | 26 |
| Ondansetron Odt | Ondansetron | 51 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 50 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 44 | 14 |
| Allopurinol | Allopurinol | 43 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | 17 |
| Riluzole | Riluzole | 42 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 11 |
| Levetiracetam | Levetiracetam | 40 | suppressed |
| Pregabalin | Pregabalin | 40 | 15 |
| Simvastatin | Simvastatin | 40 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 38 | 13 |
| Alendronate Sodium | Alendronate Sodium | 37 | 18 |
| Spironolactone | Spironolactone | 37 | 18 |
| Bupropion Xl | Bupropion Hcl | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | 11 |
| Methocarbamol | Methocarbamol | 34 | 12 |
| Mounjaro | Tirzepatide | 34 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | 15 |
| Glipizide | Glipizide | 31 | 13 |
| Jardiance | Empagliflozin | 30 | 11 |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | 12 |
| Januvia | Sitagliptin Phosphate | 29 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 29 | 11 |
| Olanzapine | Olanzapine | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | 12 |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 26 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 26 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 25 | 13 |
| Metformin Hcl Er | Metformin Hcl | 25 | 16 |
| Doxepin Hcl | Doxepin Hcl | 24 | 11 |
| Glimepiride | Glimepiride | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 23 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Prednisone | Prednisone | 21 | 12 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Calcitriol | Calcitriol | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Fluconazole | Fluconazole | 18 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Pindolol | Pindolol | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $88.68 · 4 records | Amgen Inc. | BOTOX, OTEZLA, Ohtuvayre, REPATHA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error